Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-25), Medpace Holdings's share price is MXN7022.03.
Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN305.64. Therefore, Medpace Holdings's PE Ratio for today is 22.97.
During the past 13 years, Medpace Holdings's highest PE Ratio was 297.30. The lowest was 21.92. And the median was 34.09.
Medpace Holdings's EPS (Diluted) for the
three
months ended in Jun. 2026 was MXN74.16.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN305.64.
During the past 12 months, Medpace Holdings's average EPS without NRIGrowth Rate was 26.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 29.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 33.70% per year.
During the past 13 years, Medpace Holdings's highest 3-Year average EPS without NRI Growth Rate was 38.60% per year. The lowest was 19.10% per year. And the median was 30.90% per year.
Medpace Holdings's EPS (Basic) for the
three
months ended in Jun. 2026 was MXN75.21.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN312.17.
Back to Basics: PE Ratio
Medpace Holdings (MEX:MEDP) PE Ratio Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.
Medpace Holdings PE Ratio Related Terms
Medpace Holdings PE Ratio Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's PE Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's PE Ratio falls into.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Medpace Holdings's Share Price of today is MXN7022.03. Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN305.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Medpace Holdings (MEX:MEDP) has a PE Ratio of 22.97 as of Jul. 25, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Medpace Holdings and its competitors. This is 33% below median its historical median of 34.09. Over the past decade, Medpace Holdings' PE Ratio has ranged from 21.92 to 297.30.
Is Medpace Holdings' PE Ratio too high?
Medpace Holdings' current PE Ratio of 22.97 is 33% below median its 10-year median of 34.09. Over the past 10 years, this metric has ranged from a low of 21.92 to a high of 297.30. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' PE Ratio compare to ICLR and RVTY?
Medpace Holdings' PE Ratio of 22.97 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Medpace Holdings' own PE Ratio has ranged from 21.92 to 297.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Diagnostics & Research company?
A good PE Ratio depends on the Medical Diagnostics & Research industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current PE Ratio is 22.97, which is 33% below median its own 10-year median of 34.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current PE Ratio of 22.97. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current PE Ratio is 22.97, which is 33% below median its 10-year median of 34.09. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current PE Ratio is 22.97 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
PE Ratio: 22.97 (33% below median its 10-year median of 34.09)
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for MEX:MEDP
PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
